Clinical Trials Browser

Phase 1/2 × INDUSTRY × talazoparib × Clear all

NCT04497116 2025-10-21

TRESR

Phase 1/2 Completed

276 enrolled 33 charts

Other solid neoplasm

Advanced Solid Tumor

NCT03330405 2023-10-13

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Phase 1/2 Terminated

223 enrolled 50 charts

BreastGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Recurrence

NCT03875313 2022-02-17

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Phase 1/2 Terminated

33 enrolled 14 charts

BreastGastrointestinalGenitourinary

Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03637491 2022-01-26

A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors

Phase 1/2 Terminated

36 enrolled 22 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04052204 2021-10-14

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

3 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck